Clinical Trial Update: Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant therapy trial for resectable hepatocellular carcinoma is actively recruiting, employing a multimodal deep learning model to screen patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Chen Xiaoping | Conditions: HCC | Phase 2 | Status: RECRUITING